# Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

Source: https://onco.cc/trials/nct00003456/  
OnCo record `nct00003456` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Antineoplastons in Glioma & glioblastoma, run by Burzynski Research Institute, completed.

## Summary

Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme is a phase 2 interventional study registered as NCT00003456 by Burzynski Research Institute, with 40 participants recorded, started 1995-03-14 and reaching its primary completion in 2004-12-07. Interventions recorded: Antineoplaston therapy (Atengenal + Astugenal). Conditions recorded: Glioblastoma Multiforme of Brain.

Linked to the technology Antineoplastons because the registry's title names it ("antineoplastons") and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00003456
- Phase: 2
- Setting: Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Glioblastoma Multiforme
- Sponsor: Burzynski Research Institute
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT00003456: https://clinicaltrials.gov/study/NCT00003456

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Antineoplastons (Burzynski clinic)](https://onco.cc/technologies/antineoplastons/)

---
JSON: https://onco.cc/api/v1/entities/nct00003456.json